Novavax (NVAX) Other Operating Expenses (2011 - 2026)

Novavax's Other Operating Expenses history runs 11 years deep, the most recent figure standing at $30.7 million for Q1 2026.

• In Q1 2026, Other Operating Expenses rose 117.46% year-over-year to $30.7 million; the TTM figure through Mar 2026 stood at $187.5 million (up 18.92% YoY), while the FY2024 annual figure was $51.9 million, changed N/A from the prior year.
• Other Operating Expenses was $30.7 million for Q1 2026 at Novavax, up from $22.9 million in the prior quarter.
• In the past five years, Other Operating Expenses ranged from a high of $434.6 million in Q3 2022 to a low of $14.1 million in Q1 2025.
• Historically, Other Operating Expenses has averaged $97.1 million across 5 years, with a median of $55.8 million in 2023.
• Biggest YoY gain for Other Operating Expenses was 124.19% in 2023; the steepest drop was 79.42% in 2023.
• A 5-year view of Other Operating Expenses shows it stood at $181.8 million in 2022, then dropped by 14.74% to $155.0 million in 2023, then sank by 76.34% to $36.7 million in 2024, then plunged by 37.52% to $22.9 million in 2025, then surged by 33.97% to $30.7 million in 2026.
• The last three Other Operating Expenses figures came in at $30.7 million (Q1 2026), $22.9 million (Q4 2025), and $118.5 million (Q3 2025), per Business Quant data.